RU2017140515A - Способ лечения рассеянного склероза (варианты) - Google Patents
Способ лечения рассеянного склероза (варианты) Download PDFInfo
- Publication number
- RU2017140515A RU2017140515A RU2017140515A RU2017140515A RU2017140515A RU 2017140515 A RU2017140515 A RU 2017140515A RU 2017140515 A RU2017140515 A RU 2017140515A RU 2017140515 A RU2017140515 A RU 2017140515A RU 2017140515 A RU2017140515 A RU 2017140515A
- Authority
- RU
- Russia
- Prior art keywords
- treatment
- multiple sclerosis
- subject
- options
- medicine
- Prior art date
Links
- 201000006417 multiple sclerosis Diseases 0.000 title claims 4
- 239000003814 drug Substances 0.000 claims 3
- 102000018997 Growth Hormone Human genes 0.000 claims 2
- 108010051696 Growth Hormone Proteins 0.000 claims 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 108010005714 Interferon beta-1b Proteins 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 229960003161 interferon beta-1b Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (4)
1. Применение соматотропина в количестве от 0,05 до 0,5 МЕ/кг массы тела субъекта ежедневно один или два раза в сутки в качестве лекарственного средства для лечения рассеянного склероза у субъекта.
2. Применение ИФР-1 в количестве от 50 до 500 мкг/кг массы тела субъекта ежедневно один или два раза в сутки в качестве лекарственного средства для лечения рассеянного склероза у субъекта.
3. Применение физиологического индуктора соматотропина и/или ИФР-1 в терапевтически эффективном количестве в качестве лекарственного средства для лечения рассеянного склероза у субъекта.
4. Применение по любому из пп. 1-3, где лечение дополнительно включает введение указанному субъекту рекомбинантного человеческого интерферона-β-1b.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2017140515A RU2721282C2 (ru) | 2017-11-21 | 2017-11-21 | Способ лечения рассеянного склероза (варианты) |
PCT/RU2018/050142 WO2019103660A1 (en) | 2017-11-21 | 2018-11-18 | Method of multiple sclerosis treatment (variants) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2017140515A RU2721282C2 (ru) | 2017-11-21 | 2017-11-21 | Способ лечения рассеянного склероза (варианты) |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2017140515A3 RU2017140515A3 (ru) | 2019-05-21 |
RU2017140515A true RU2017140515A (ru) | 2019-05-21 |
RU2721282C2 RU2721282C2 (ru) | 2020-05-18 |
Family
ID=66630780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2017140515A RU2721282C2 (ru) | 2017-11-21 | 2017-11-21 | Способ лечения рассеянного склероза (варианты) |
Country Status (2)
Country | Link |
---|---|
RU (1) | RU2721282C2 (ru) |
WO (1) | WO2019103660A1 (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116059213A (zh) * | 2023-03-29 | 2023-05-05 | 信义核新(北京)生物科技有限公司 | 一种化合物及其盐在癌症治疗药物中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965531A (en) * | 1995-08-31 | 1999-10-12 | National Institutes Of Health | Method of reducing perivascular lesions using insulin-like growth factor I |
US6187750B1 (en) * | 1999-08-25 | 2001-02-13 | Everyoung Technologies, Inc. | Method of hormone treatment for patients with symptoms consistent with multiple sclerosis |
JP2005534650A (ja) * | 2002-06-11 | 2005-11-17 | ザ バーナム インスティテュート | エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用 |
EP3130349A1 (en) * | 2004-06-04 | 2017-02-15 | Genentech, Inc. | Method for treating multiple sclerosis |
WO2010025321A2 (en) * | 2008-08-28 | 2010-03-04 | Facet Biotech Corporation | Method for treating multiple sclerosis patients with anti-il2r antibodies |
BRPI0922969A2 (pt) * | 2008-12-19 | 2019-09-24 | Univ Indiana Res & Tech Corp | pró-farmaco de amida baseado na superfamília de glucagon peptídeo. |
-
2017
- 2017-11-21 RU RU2017140515A patent/RU2721282C2/ru active
-
2018
- 2018-11-18 WO PCT/RU2018/050142 patent/WO2019103660A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2019103660A1 (en) | 2019-05-31 |
RU2017140515A3 (ru) | 2019-05-21 |
RU2721282C2 (ru) | 2020-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019011215A (es) | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. | |
SA519402217B1 (ar) | مثبطات إيميدازو بيرازين لكيناز تيروسين بروتون | |
MX2019012884A (es) | Terapia de combinacion. | |
WO2019032662A8 (en) | Clec9a binding agents and use thereof | |
EP4241850A3 (en) | Mdm2 inhibitors and combinations thereof | |
WO2016018920A8 (en) | Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions | |
EP3211001A3 (en) | Superagonists and antagonists of interleukin-2 | |
RU2739037C3 (ru) | Композиция для контролируемой стимуляции яичников | |
MX2016010899A (es) | A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22. | |
RU2017116973A (ru) | Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса | |
MX2016012799A (es) | Metodos para tratar el virus de la hepatitis c. | |
MX2015012536A (es) | Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc. | |
MX2020011333A (es) | Uso terapeutico de proteinas morfogeneticas oseas. | |
MX2020008208A (es) | Agentes de unión a fibroblastos y uso de estos. | |
PH12019550241A1 (en) | Mic-1 compounds and uses thereof | |
RU2018119359A (ru) | Способ индукции пролиферации кардиомиоцитов и лечения заболеваний сердца | |
MX2021008207A (es) | Proteínas de fusión multifuncionales y usos de las mismas. | |
MX2018002223A (es) | Derivados de insulina novedosos y usos medicos de los mismos. | |
CR20220089A (es) | Proteínas de fusión terapéuticas | |
MX2021003109A (es) | Proteina para el tratamiento de enfermedades inflamatorias. | |
MX2018000240A (es) | Metodos para tratar el vhc. | |
MX2023000398A (es) | Analogos de insulina novedosos y usos de estos. | |
MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
RU2017140515A (ru) | Способ лечения рассеянного склероза (варианты) | |
PH12021551174A1 (en) | Novel folr1 specific binding proteins for cancer diagnosis and treatment |